Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fauci: Borrowed Cash Won't Carry Zika Efficacy Trials

Executive Summary

Cash borrowed from various US government programs, including the Ebola response, is enough to get at least two Phase I Zika vaccine trials underway, but those funds won't carry the efficacy studies – the preparations of which must get off the ground next month. So Congress needs to allocate new dollars within the next few weeks or the Phase II trials will be in jeopardy, Anthony Fauci, the nation's top infectious disease official, told Scrip.

You may also be interested in...

Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract

Takeda is officially in the ballgame, joining the ranks of other firms like Sanofi Pasteur and GlaxoSmithKline, to find a vaccine against the Zika virus after snagging a US government R&D contract worth up to $312m.

Emerging Diseases: Disruptive, Commercially Risky, But GSK Has A Solution

GlaxoSmithKline PLC has offered up its new Maryland vaccine research and development center, and its scientists, under the company's proposal to establish a global collaboration for the pursuit of products that are commercially risky, but necessary to address emerging infectious diseases, before a public health crisis strikes.

Zika Funds Stuck In Political Fight; Vaccines Continue On Borrowed Cash

A $1.1bn Zika funding measure failed in a Senate procedural vote on June 28, leaving US government agencies to continue their work on dollars borrowed from other programs, while Republicans and Democrats argued over who's to blame.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts